High Expression of lncRNA AFAP1-AS1 Promotes the Progression of Colon Cancer and Predicts Poor Prognosis

Hao Bo,Liqing Fan,Jingjing Li,Zhizhong Liu,Shanshan Zhang,Lei Shi,Can Guo,Xiayu Li,Qianjin Liao,Wenling Zhang,Ming Zhou,Bo Xiang,Xiaoling Li,Guiyuan Li,Wei Xiong,Zhaoyang Zeng,Fang Xiong,Zhaojian Gong
DOI: https://doi.org/10.7150/jca.26461
IF: 3.9
2018-01-01
Journal of Cancer
Abstract:Long non-coding RNAs (lncRNAs) are dysregulated in various cancers. However, the clinical relevance and functional roles of AFAP1-AS1 in colon cancer (CC) have not been clarified. We analyzed the lncRNA expression patterns in Gene Expression Omnibus (GEO) datasets and the Cancer Genome Atlas (TCGA) RNA-seq datasets, and found that the expression level of AFAP1-AS1 was significantly elevated in CC tissues. High levels of AFAP1-AS1 were associated with poor disease-free survival and overall survival in CC patients. <i>In vitro</i> experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the cell invasive and migration capability in CC cell line HT-29. AFAP1-AS1 knockdown also increased the expression of E-cadherin and ZO-1 while inhibited the expression of Vimentin, MMP9, ZEB1 and β-catenin, suggesting that AFAP1-AS1 is involved in the epithelial-mesenchymal transition (EMT) process of CC. Further studies confirmed that AFAP1-AS1 knockdown also affected the actin-cytokeratin signaling pathway. Thus, AFAP1-AS1 might be a potential novel diagnostic marker and therapeutic target for CC.
oncology
What problem does this paper attempt to address?